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Evaluation of a phosphate management protocol to achieve optimum serum phosphate 
levels in haemodialysis patients 
 
Abstract 
Objective:  To evaluate the effectiveness of a protocol designed to optimise serum phosphate 
levels in patients undergoing regular haemodialysis. 
Design:  Randomised, controlled trial. 
Setting:  Haemodialysis units at Barts and the London NHS Trust and satellite units. 
Patients:  Thirty-four clinically stable adults undergoing regular haemodialysis with a serum 
phosphate level >1.8 mmol/l on at least one occasion within 4 months of starting the study. 
Intervention:  Management of serum phosphate using a specially designed phosphate 
management protocol during a 4-month study period implemented by a renal dietitian and renal 
pharmacist compared to standard practice. 
Main outcome measure:  Change in serum phosphate levels in both groups after 4 months. 
Results:  Patients managed using the phosphate management protocol had a significantly greater 
reduction in serum phosphate levels compared to patients receiving standard practice (-0.22 ± 
0.67 vs +0.19 ± 0.32 mmol/l, P = 0.03). 
Conclusion:  The phosphate management protocol was effective and its implementation 
associated with significantly better serum phosphate control in patients undergoing regular 
haemodialysis. 
 
 
Five key words:  Haemodialysis;  phosphate;  protocol;  pharmacist;  dietitian. 
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Introduction 
Patients undergoing regular haemodialysis (HD) are at risk of complications associated with 
elevated serum phosphate levels which increasingly stimulate parathyroid gland production of 
parathyroid hormone (PTH) and proliferation and lead to accelerated bone resorption.
1
  
Hyperphosphataemia and hypercalcaemia also increase the calcium–phosphate product, 
potentiating metastatic calcification in soft tissues.
2
  In addition, patients with elevated serum 
phosphate experience higher mortality and those with serum phosphate levels above 2.1mmol/l 
have a significantly increased risk of dying during their first year of treatment.
3
 
 
Standard thrice weekly HD is unable effectively to remove excess phosphate from the blood
4
 and, 
therefore, patients need to restrict their dietary intake of food rich in phosphate and to take oral 
phosphate binders to control both serum phosphate and PTH levels.
5
  Traditionally, patients are 
taught about the importance of both their diet and medication at the start of regular haemodialysis 
and this is reinforced as treatment continues.  A number of studies have evaluated the efficacy of 
such teaching.
6,7,8,9
  Although some were unable to show a clinical benefit from teaching,
7,8
 others 
reported that higher levels of knowledge about diet and medication and receiving education from 
a dietitian were associated with lower serum phosphate levels.
6,9
 
 
However, in spite of these interventions, hyperphosphataemia remains a problem for a substantial 
number of HD patients
10
 and there is a need to investigate standardised and reproducible 
protocols to facilitate the management of hyperphosphataemia.  To this end, a phosphate 
management protocol was devised to enable renal dietitians and renal pharmacists to extend their 
traditional role in this area of practice under the auspices of a Patient Group Direction.
11
  The aim 
of this study was to evaluate the effectiveness of the protocol, designed to optimise serum 
phosphate levels in patients undergoing regular haemodialysis. 
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Methods 
Subjects 
The subjects were recruited from adult outpatients with chronic renal failure undergoing regular 
haemodialysis (three times per week) and attending daytime sessions at Barts and the London 
(BLT) NHS Trust between June 2003 and September 2003.  Inclusion criteria were age over 18 
years, clinically stable, English speakers, mentally alert and elevated serum phosphate;  patients 
with malignancy, gastrointestinal disorders including malabsorption, and planned surgery were 
excluded.  Before entry into the study, serum phosphate levels were monitored for 4 months and 
patients with at least one value >1.8mmol/l during this period were invited to participate in the 
study.  A total of thirty-four patients fitted the study criteria, agreed to participate and provided 
informed written consent.  They were randomised into one of two study groups using a computer 
generated random number list: 
i. Phosphate management protocol (PMP) group 
ii. Standard practice (SP) group 
At recruitment, the two groups were comparable in terms of age, sex, ethnic group, aetiology of 
kidney disease, length of time since commencing regular haemodialysis and body mass index 
(BMI) (Table 1).  All study patients were reviewed and blood results monitored once per month 
for the 4-month duration of the study.  At each monthly visit, all patients were seen individually 
by a renal dietitian who devised an individual care plan.  The individual dietary advice was given 
after taking a diet history
12
 and comprised verbal advice supported by either a detailed low 
phosphate diet booklet providing a comprehensive list of high-phosphate foods to avoid and 
suitable alternatives, or a simplified handwritten diet action plan.  The choice of written material 
was based on each patient's circumstances and their perceived ability to understand the 
instructions given.  Patients were advised whilst they were undergoing dialysis. 
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Phosphate management protocol group 
In the PMP group, phosphate binder and alfacalcidol (vitamin D analogue) medication was 
adjusted using a specially designed phosphate management protocol.  This was developed by the 
multi-disciplinary renal research team which included a renal consultant, dietitian and 
pharmacists.  The protocol comprised two algorithms (Figure 1) that allowed the renal research 
pharmacists and renal research dietitian, working together, to change patients' medication as 
specified within the protocol without close supervision of a renal consultant.  The protocol was 
approved by the BLT Patient Group Direction Committee.
11
  The algorithms were used to inform 
changes to the dose and type of phosphate binder and the dose of alfacalcidol required to improve 
patients’ serum phosphate, calcium and intact parathyroid hormone (iPTH) levels.  Once per 
month, whilst the patients were undergoing dialysis, the renal research pharmacists explained the 
changes to their medication, counselled them about when to take them and adjustments in relation 
to the size of their meals, and provided a medication card.  Once per month, the patients were 
also seen by the renal research dietitian.  
 
Standard practice group 
In the SP group, a senior doctor within the renal team reviewed the monthly blood results and the 
dose and type of phosphate binder and alfacalcidol during dialysis ward rounds or at an outpatient 
clinic.  Once per month, the patients were also seen by a renal dietitian but were not seen by a 
pharmacist. 
 
Monitoring 
Routine blood samples were taken before dialysis within the first week of every month;  serum 
was separated and frozen within 1 hour of blood collection.  Serum phosphate and calcium 
concentrations were analysed using ultraviolet and colour photometric tests respectively
13,14
 and 
calcium-phosphate product (Ca x P) was calculated.  Serum calcium concentrations were adjusted 
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with reference to serum albumin (corrected calcium (mmol/l) = measured calcium (mmol/l) + 
([40 – albumin (g/l)] x 0.02).  Serum iPTH and aluminium concentrations were measured at the 
beginning and end of the study by an automated chemiluminescent immunoassay and atomic 
absorption spectrophotometry respectively.
15,16
  Adequacy of haemodialysis was assessed by 
single-pool Kt/V calculated at recruitment and at the end of the study.
17
  Weight was recorded at 
the end of each dialysis session and using previously recorded height, BMI was calculated. 
 
Statistical analysis 
Power calculations indicated that a sample size of 17 patients in each group was required to 
detect a 15% reduction in serum phosphate levels (80% power at a significance level of 0.05) 
based on data from BLT haemodialysis patients in 2000.  The distribution of variables was tested 
for normality using the Shapiro-Wilks’ test (SAS 8.2, 2001, SAS Institute Inc, Cary, USA). 
 
At baseline, comparisons were made between the two patient groups using unpaired t tests for 
normally distributed data, (most biochemical / nutritional variables, age) and Mann Whitney U 
tests for data not normally distributed (iPTH, time on dialysis).  The difference between the 
baseline and post-intervention results within each group were compared using paired t-tests and 
the Wilcoxon matched pairs test.  The difference between the change from baseline to post-
intervention in the two groups was evaluated using unpaired t tests and Mann Whitney U tests.  
Categorical data were compared using the chi-squared test (male to female ratio) and McNemar’s 
test and Cochran’s test for linear trend (number of patients achieving the K/DOQI targets18) 
(Systat 10.2, 2002, Systat Software UK Limited, Hounslow, UK). 
 
The study protocol was approved by North East London Strategic Health Authority (NELSHA) 
Research Ethics Committee, reference number P/01/092. 
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Results 
Forty-two patients were recruited into the study and randomised to one of the two intervention 
groups;  34 of these received the interventions (Figure 2).  Three patients did not complete the 
study and all of these were allocated to the PMP group;  two were withdrawn in week 6 after 
developing complicated or confounding medical conditions (total parathyroidectomy for severe 
hyperparathyroidism and oropharyngeal squamous cell carcinoma requiring feeding via a 
gastrostomy) and the third died from septicaemia secondary to endocarditis in week 9.  The data 
from these patients were included in the comparative analysis at recruitment (Table 1) but not in 
subsequent analyses. 
 
Haemodialysis adequacy, as indicated by Kt/V, was comparable between the two groups at 
recruitment (PMP 1.30 ± 0.25 vs SP 1.32 ± 0.17, P=0.77) and at the end of the study (PMP 1.29 ± 
0.29 vs SP 1.43 ± 0.20, P=0.14).  Only one patient (SP group) had an elevated serum aluminium 
level before the intervention (2.6 μmol/l).  This responded to reducing her aluminium hydroxide 
dose.  In all other patients, aluminium levels remained within acceptable limits throughout the 
study.  BMI remained comparable in both groups throughout the study. 
 
No statistically significant difference was observed in serum phosphate concentrations, corrected 
calcium, Ca x P or iPTH between the two groups at the start of the study (Table 2).  However, 
after the study, a significant increase in serum phosphate was observed in the SP group whilst the 
PMP group showed a small, insignificant reduction.  A comparison between the two groups over 
the study period showed a significantly greater improvement in serum phosphate levels in the 
PMP group compared to the patients receiving standard practice (-0.22 ± 0.67 vs 0.19 ± 0.32 
mmol/l, P=0.03).  Parallel differences in the change in Ca x P product were observed between the 
two groups but there were no significant differences in the change in serum corrected calcium or 
iPTH levels (Table 2). 
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The proportion of patients achieving the K/DOQI target for serum phosphate increased in the 
PMP but decreased in the SP group following the intervention period but the changes were not 
significant within groups (Table 3) or between groups (data not shown).  Similarly, the proportion 
of patients meeting multiple K/DOQI targets increased in the PMP and decreased in the SP group 
but again these trends were not significant (Table 4). 
 
Significantly more changes to the dose of individual phosphate binders were made in the PMP 
group than in the SP group (median [range] number of dose changes, PMP 5[1-7] vs SP 0 [0-3], 
P<0.001).  The estimated time spent with patients in the PMP group each month by the 
pharmacists was 19 [8-25] minutes;  patients in the SP group were not seen by the pharmacists. 
 
Eight breaches of the study protocol occurred during the study relating to physicians changing 
binders between monthly reviews without reference to the protocol.  On each occasion, when the 
breach was identified by the pharmacist, the blood levels were reviewed promptly against the 
protocol and an appropriate amendment made in compliance with the protocol. 
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Discussion 
The results from the current study show that use of a defined phosphate management protocol can 
lead to statistically significantly improved phosphate control over a 4-month period compared 
with standard therapy.  Although a number of previous studies have evaluated the effects of 
single elements of managing hyperphosphataemia, including dietary counselling and 
education
6,7,8,9,19,20
 and pharmacotherapy,
21,22
 few have investigated an algorithm-based protocol 
for the management of hyperphosphataemia.  Craven and Moreschi
23
 examined the effects of a 
protocol for administering intravenous calcitriol in haemodialysis patients and concluded that it 
decreased the incidence of elevated iPTH levels although no control group was included. 
 
The use of dietary modification and pharmacotherapy is not without risk in this patient 
population.  Dietary phosphate is associated with dietary protein and over-restriction may 
compromise nutritional adequacy
24
 and lead to undernutrition with its accompanying risk of 
increased mortality.
25
  No dietary data were collected during this study so the adequacy of 
patients’ nutritional intake is unknown.  However, BMI data suggest that the patients who 
participated in the study were likely to be well-nourished and no significant decrease in BMI was 
observed over the 4-month duration of either arms of the study.  Calcium-containing phosphate 
binders are associated with progressive cardiovascular calcification
26,27
 whilst patients taking 
those containing aluminium have an increased risk of aluminium toxicity manifesting as 
encephalopathy and osteomalacia.
28,29
  In the present study, elevated serum aluminium levels 
were not a concern.  Non-absorbable sevelamer is associated with fewer serious adverse effects, 
although gastrointestinal symptoms have been reported
30,31
 and it is one of the most expensive 
phosphate binders available.
32
  It has been speculated that by utilising a combination of phosphate 
binders in a systematic manner, the protocol might also reduce the risks associated with 
individual binders.
22
  A large prospective study would be required to address this. 
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The total staff time required to deliver the phosphate management protocol compared with the 
standard treatment was not measured.  Although, anecdotally no additional medical staff time 
was required with the PMP group, additional pharmacist and dietetic time was required.  It could 
be argued that the additional staff time, rather than the protocol per se contributed to improved 
phosphate control.  Future studies are needed to evaluate this and to explore the health economic 
implications of the protocol with regard to both staff time and prescribing costs. 
 
The limitations of the study include the small number of patients studied.  Although a statistically 
significant difference in the change of phosphate levels has been observed between the two 
groups, this small change is unlikely to have clinical significance.  However, this could be 
explored in a future study by repeating the study in patients with more poorly controlled serum 
phosphate rather than in a population with a single serum phosphate level above 1.8mmol/l.  It 
would be beneficial to also measure the residual renal function of patients, which was not done in 
the present study, in order to clarify their ability to control their serum phosphate.  In future 
studies, the additional measurement of nutrient intake would allow the effect of dietary advice on 
phosphate intake to be directly evaluated as well as facilitating the examination of overall nutrient 
intake adequacy. 
 
This study has shown that patients undergoing regular haemodialysis had significantly better 
serum phosphate control whilst managed with a protocol incorporating patient education, dietary 
counselling and pharmacotherapy than patients receiving standard management.  A larger study is 
required to confirm whether the observed effects can be extended to other dialysis populations. 
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Table 1 
Demographic, clinical and nutritional characteristics of the 34 randomised patients at recruitment.  
Values are expressed as mean ± SD except where indicated 
 Phosphate 
management protocol 
group 
(n = 17) 
Standard practice 
group 
 
(n = 17) 
P value 
Age (years) 51.1 ± 12.7          47.6 ± 14.4 0.46 
Male : female ratio (n) 11M : 6F 12M : 5F 0.71 
Race (n) 
Black 
Indoasian 
White 
Other 
 
5 
1 
11 
0 
 
4 
2 
10 
1 
 
Aetiology (n) 
Glomerulonephritis 
Diabetes 
Hypertension 
Adult polycystic kidneys 
Pyelonephritis 
Unknown 
Other
a
 
 
5 
3 
2 
1 
0 
2 
4 
 
2 
2 
3 
2 
2 
2 
4 
 
Length of time on 
haemodialysis (years) 
2.0 (<1 – 10) 2.5 (<1 – 7) 0.5 
Nutrition 
Height (m) 
Weight (kg) 
BMI (kg/m
-2
) 
 
1.71 ± 0.10 
71.1 ± 15.8 
24.3 ± 4.8 
 
1.66 ± 0.10 
71.7 ± 13.1 
26.3 ± 5.5 
 
0.13 
0.90 
0.27 
 
a
Include focal segmental glomerulosclerosis, IgA nephropathy, oxalosis, tuberculosis, 
Goodpasture's syndrome 
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Table 2 
Effect of phosphate management protocol and standard practice on biochemical variables in patients undergoing regular haemodialysis (mean ± 1SD 
except where stated). 
 Phosphate management protocol (n=14) Standard practice (n=17) Intergroup 
P value 
Before
 
Intergroup 
P value 
Change 
 
 Before After Change Intragroup 
P value 
Before After Change Intragroup
P value 
Serum phosphate 
(mmol/l) 
2.03±0.28 1.81±0.54 -0.22±0.67 0.24 1.88±0.32 2.07±0.25 +0.19±0.32 0.03 0.18 0.03 
Corrected calcium 
(mmol/l) 
2.48±0.26 2.47±0.15 -0.01±0.28 0.95 2.34±0.26 2.34±0.26 0±0.16 0.92 0.15 0.91 
Ca x P 
(mmol
2
/l
2
) 
5.01±0.74 4.43±1.20 -0.58±1.62 0.20 4.38±0.86 4.80±0.51 +0.41±0.81 0.05 0.04 0.04 
iPTH
a
 
(pmol/l) 
36 
(0.3-224) 
51 
(0.3-175) 
-2 
(-75 to +40) 
0.38 29 
(0.3-237) 
21 
(0.3-165) 
0 
(-214 to +26) 
0.64 0.85 0.89 
a
median (range) 
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Table 3 
Effect of phosphate management protocol and standard practice on patients achieving individual K/DOQI targets
18
 
K/DOQI targets for serum 
variables 
 Number (%) of patients with serum variable within target P value 
Before After 
PO4 
(1.13-1.80 mmol/l) 
PMP (n=14) 2 (14) 5 (36) 0.08 
SP (n=17) 7 (41) 3 (18) 0.10 
Corrected calcium 
(2.1-2.37 mmol/l) 
PMP (n=14) 5 (36) 4 (29) 0.56 
SP (n=17) 7 (41) 5 (29) 0.41 
Ca x P product 
(<4.44 mmol
2
/
2
) 
PMP (n=14) 3 (21) 7 (50) 0.16 
SP (n=17) 10 (59) 5 (29) 0.06 
IPTH 
(16.0-33.0 pmol/l) 
PMP (n=14) 1 (7) 1 (7) 1.00 
SP (n=17) 2 (12) 4 (24) 0.32 
Comparisons undertaken using a McNemar test
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Table 4 
Effect of phosphate management protocol and standard practice on patients achieving multiple K/DOQI targets
18
 
  Number (%) of patients achieving K/DOQI P value 
Targets achieved 0 1 2 3 4 
Phosphate management 
protocol (n=14) 
Before 6 (43) 5 (36) 3 (21) 0 0 
0.18 
After 3 (21) 6 (43) 4 (29) 1 (7) 0 
Standard practice (n=17) 
Before 4 (23) 3 (18) 7 (41) 3 (18) 0 
0.10 
After 5 (30) 7 (41) 5 (29) 0 0 
Comparisons undertaken using a Cochran test for linear trend 
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Figure 1 
Phosphate management protocol algorithms 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Serum phosphate increased 
(> 1.8mmol/l) 
Corrected calcium in normal range 
(2.1-2.75 mmol/l)* 
 
Start/  dose phosphate binder. 
If corrected calcium is consistently at the 
upper end of the normal range, consider 
switch to non-calcium phosphate binder 
(aluminium or sevelamer) 
 
PTH 10 -20pmol/l 
Maintain dose alfacalcidol 
 
PTH >20pmol/l 
Start/  dose alfacalcidol (only after 
achieving phosphate level in target range) 
 
Refer 
 PTH <10pmol/l 
 PTH >100pmol/l consistently 
 If max dose alfacalcidol reached 
 High aluminium level 
Corrected calcium  
(<2.2 mmol/l)* 
 
Start/  dose calcium-containing 
phosphate binder 
 
PTH <10pmol/l (unlikely scenario) 
Stop/ ↓ dose alfacalcidol 
 
PTH 10-20pmol/l 
Start/ maintain dose alfacalcidol 
 
PTH >20pmol/l 
Start/  dose alfacalcidol (only after 
achieving phosphate level in target 
range) 
 
Refer 
 PTH <10pmol/l 
 PTH >100pmol/l consistently 
 Corrected Calcium <2mmol/l 
 If max dose alfacalcidol reached 
 High aluminium level 
Corrected calcium   
(>2.65 mmol/l)* 
 
Stop/  dose calcium-containing 
phosphate binder 
 
Start/  dose non-calcium phosphate 
binder (aluminium or sevelamer) 
 
Stop alfacalcidol if: 
EITHER  
Corrected Calcium >3.0mmol/l 
OR 
Persistent Corrected Calcium 
>2.7mmol/l after reduction of dose of 
calcium-containing phosphate binder 
 
Refer 
 PTH <10pmol/l 
 PTH >100pmol/l consistently 
 High aluminium level 
 Corrected calcium level consistently 
>2.7mmol/l, with no obvious 
explanation, OR >3mmol/l on any 
one occasion 
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Figure 1 continued 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*There is a small overlap in the threshold corrected calcium levels of the three treatment pathways so that patients whose levels fluctuate around these values do 
not have their medication adjusted at every review
Phosphate in normal range 
(0.8 – 1.7mmol/l) 
Corrected calcium  
(<2.2 mmol/l)* 
 
Start/  dose calcium-containing phosphate 
binder 
 
 dose non-calcium containing phosphate 
binder if appropriate 
 
Start/  dose alfacalcidol, if both Corrected 
Calcium and Phosphate levels are at lower end 
of target ranges 
 
Refer 
 PTH <10pmol/l 
 PTH consistently >100pmol/l 
 Corrected Calcium <2mmol/l 
 If max dose alfacalcidol reached 
 
Corrected calcium in normal range 
(2.1-2.75 mmol/l)* 
 
PTH 10 - 20pmol/l 
No change 
 
PTH > 20pmol/l 
Start/  dose alfacalcidol (only after achieving 
phosphate level in target range) 
 
Consider start/  dose phosphate binder, 
especially if CorCa and PO4 at upper end of 
range 
 
Refer 
 PTH <10pmol/l 
 PTH consistently >100pmol/l 
 If max dose alfacalcidol reached 
 
Corrected calcium  
(>2.65 mmol/l)* 
 
PTH 10 - 20pmol/l 
 dose calcium-containing phosphate binder 
initially AND consider start/  dose of non-
calcium containing phosphate binder 
 dose alfacalcidol also, if corrected calcium 
level is consistently >2.7mmol/l 
 
PTH > 20pmol/l 
As above 
 
Refer 
 PTH <10pmol/l 
 PTH consistently >100pmol/l 
 Corrected calcium level consistently 
>2.7mmol/l, with no obvious explanation, 
OR >3mmol/l on any one occasion 
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Figure 2 
Flow of participants through trial 
 
       
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility 
(n = 58) 
Excluded (n = 16) 
 
12 refused to participate 
2 did not meet inclusion criteria 
2 died 
Analyzed (n = 14) 
 
Received PMP (n = 17) 
 
Completed (14)  Lost to follow-up (0) 
Discontinued PMP (3) 
1 died 
1 total parathyroidectomy 
1 squamous cell carcinoma  
 
Allocated to PMP (n = 22) 
 
Received PMP (17)  Did not receive PMP (5) 
1 withdrew consent 
1 renal transplant 
2 clinically unstable 
1 holiday abroad 
Received SP (n = 17) 
 
Completed (17)  Lost to follow-up (0) 
   Discontinued SP (0) 
 
 
Allocated to SP (n = 20) 
 
Received SP (17) Did not receive SP (3) 
1 withdrew consent 
1 died 
1 lymphoma 
        
Analyzed (n = 17) 
 
Randomization 
(n = 42) 
‘Before’  
blood samples 
‘After’  
blood samples 
